title: [Usefulness of TS-1 and lentinan combination immunochemotherapy in advanced or recurrent gastric cancer--pilot study aiming at a randomized trial].
abstract: The quality of life (QOL) of patients with advanced or recurrent gastric cancer is poor and their immunocompetence is low, making it important to conduct chemotherapy while at the same time improving their QOL and maintaining their immunocompetence. To improve QOL and increase compliance by reducing the side effects but not the antitumor effect of TS-1, a 2-week regime with 2-week administration of TS-1, and a 1-week drug-free interval in combination with the immunotherapeutic agent lentinan (LNT) was started in 5 patients with advanced or recurrent gastric cancer. Toxicity, efficacy, QOL, and immunological parameters were investigated preliminarily to examine whether or not usefulness of lentinan could be evaluated. QOL scores for appetite, nausea/vomiting, and abdominal pain/diarrhea showed improvement, although not in statistically significant values. The Th2 (CD4-positive, IL4-positive T cells) response in peripheral blood decreased significantly. TS-1 and lentinan combination immunotherapy was carried out safely with advanced recurrent gastric cancer. In order to examine the usefulness of LNT combined use, it was thought that a randomised trial using toxicity with not only efficacy but QOL and immunological parameters as indicators would be beneficial.
authors.affiliation: Gastrointestinal Research Center, Dept. of Surgery, Minoh City Hospital.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kimura
authors.forename: Shouhei
authors.initials: S
authors.lastname: Iijima
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kato
authors.forename: Masaki
authors.initials: M
authors.lastname: Tsujie
authors.forename: Yasuto
authors.initials: Y
authors.lastname: Naoi
authors.forename: Taro
authors.initials: T
authors.lastname: Hayashi
authors.forename: Takahiko
authors.initials: T
authors.lastname: Tanigawa
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Yamamoto
authors.forename: Eiji
authors.initials: E
authors.lastname: Kurokawa
authors.forename: Nobuteru
authors.initials: N
authors.lastname: Kikkawa
authors.forename: Nariaki
authors.initials: N
authors.lastname: Matsuura
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007121:Immunocompetence / Q000187:drug effects; D007912:Lentinan / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011788:Quality of Life; D017640:Silicates / Q000008:administration & dosage*; D013274:Stomach Neoplasms / Q000188:drug therapy*; D014025:Titanium / Q000008:administration & dosage*
chemical_list: D017640:Silicates; C103828:titanium silicide; D007912:Lentinan; D014025:Titanium